Company intelligence / Profile preview

American Diversified Holdings

Del Mar, California, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

GlucoGuard is a patent-pending nocturnal glucose monitoring and delivery system in development stage. The FDA reviewed the breakthrough device application and confirmed it represents breakthrough technology with no approved alternatives for nocturnal hypoglycemia, meeting an unmet medical need. The company is conducting an FDA-requested sleep study safety trial to address aspiration risk and glucose delivery efficacy.[2]

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Arete Biosciences (bioengineering/device design)Dexcom (continuous glucose monitoring integration)Arizona State University (research partnership)UC Irvine (research partnership)Johns Hopkins School of Medicine (advisory)

Beyond the preview

Go deeper on American Diversified Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on American Diversified Holdings.

Explore the full profile